Skip to main content

Search Results

Displaying: 1 - 9 of 9 Results

Oral delivery of vaccines

Researchers in Samir Mitragotri’s lab have developed a platform technology that can deliver vaccines through oral administration. The technology features ionic liquids, salts that exist in the liquid phase at room temperature, that preserve protein…

Investigators

  • Samir Mitragotri

Utilizing the herpes simplex virus-based vaccine vectors to develop a COVID-19 vaccine

Researchers in the lab of David Knipe have constructed the HSV-1 based vaccine vector HSV-1 d106S. The vector can express viral, bacterial, or cancer gene products has been used to induce protective immunity in humanized mice against HIV and rhesus…

Investigators

  • David Knipe

Novel adjuvants to enhance adaptive immune response of vaccines

Researchers in the lab of Ulrich von Andrian have discovered a novel adjuvanting behavior of a clinically approved and well-tolerated class of medicines known as bisphosphonates. The team is hoping to collaborate with manufacturers of COVID-19…

Investigators

  • Ulrich von Andrian

Self-adjuvanting mRNA platform technology

Researchers in the lab of Prof. George Church at Harvard Medical School have developed a vaccine platform technology that can be applied to fields such as infectious diseases and oncology therapeutics. The team is looking to further demonstrate…

Investigators

  • George Church

Membrane protein nanoparticles for antigen presentation

Researchers in the lab of Dr. James Chou have engineered a new way to display membrane proteins to enhance vaccine immunogenicity using functionalized nanoparticles. The lab has successfully displayed several viral peptides using this technique and…

Investigators

  • James Chou

Platform for AAV Delivery to Skin

Emerging startup: A platform technology from George Church's lab enables delivery of gene therapy via the skin. (Image credit: Carl Schoellhammer, Denitsa Milanova, Humberto Trevino, Cody Cleveland, Jeff Wyckoff, Anna Mandinova, George Church,…

Investigators

  • George Church

Oral delivery of biologics

Biologics are used to treat a variety of chronic diseases including diabetes and arthritis. Not surprisingly, they command a large share of the therapeutics market. Moreover, a large number of therapeutic proteins are currently in clinical…

Investigators

  • Samir Mitragotri

A fusion intermediate state of HIV-1 gp41, targeted by broadly neutralizing antibodies, for purposes of vaccination

HIV infection generally induces a strong antibody response to the envelope glycoprotein, the sole antigen on the virion surface. Most of the induced antibodies are ineffective in preventing infection, however, as they are either non-neutralizing or…

Investigators

  • Stephen Harrison
  • Gary Frey
  • Bing Chen

Controlled delivery of TLR agonists in structural polymeric devices

Scientist at the Mooney lab demonstrated that three different types of pathogens could be incorporated to act as adjuvant in cancer vaccines. They have successfully incorporated three Toll-like receptor agonists (TLR) within a structural polymeric…

Investigators

  • David Mooney
  • Omar Ali
  • Glenn Dranoff

Page 1 of 1